T1 INTRAVENOUS SALBUTAMOL REDUCED ALVEOLAR-CAPILLARY PERMEABILITY AND EXTRA-VASCULAR LUNG WATER IN ARDS: RESULTS OF THE BALTI STUDY
T2 ABSENCE OF PROTEINASE ACTIVATED RECEPTOR-1 SIGNALLING AFFORDS PROTECTION FROM EXPERIMENTALLY INDUCED LUNG INFLAMMATION AND FIBROSIS
T3 EPITHELIAL TO MESENCHYMAL TRANSITION IN CLINICALLY STABLE LUNG TRANSPLANTATION
T4 HYPOXIA INHIBITS NEUTROPHIL APOPTOSIS VIA HYPOXIA INDUCIBLE FACTOR (HIF)-1α-DEPENDENT REGULATION OF NFκB
T5 Mechanisms regulating matrix metalloproteinase gene expression and secretion in pulmonary tuberculosis
T6 CONSEQUENCES OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN PATIENTS WITH STABLE COPD
S1 RESPIRATORY MUSCLE WEAKNESS AND PERIPHERAL MUSCLE WEAKNESS IN SUBMAXIMAL AND MAXIMAL EXERCISE IN PATIENTS WITH COPD
S2 DECLINE IN QUADRICEPS STRENGTH OVER TIME IN PATIENTS WITH COPD
S3 MID-UPPER ARM CIRCUMFERENCE PROVIDES A GOOD INDICATOR OF BODY MASS INDEX IN PATIENTS WITH COPD
S4 DISTRIBUTION OF FAT FREE MASS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
S5 TAILORED DIETARY ADVICE AND FOOD FORTIFICATION RESULTS IN WEIGHT GAIN AND CLINICAL BENEFIT IN MALNOURISHED PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
S6 POTENTIAL THERAPEUTIC ROLE FOR A NOVEL CYTOKINE EBI3-P35 IN ALLERGIC AIRWAY INFLAMMATION
S7 ELEVATED MEMBRANE BOUND TNFα ON PERIPHERAL BLOOD MONOCYTES OF ADULTS WITH REFRACTORY ASTHMA
S8 SPUTUM AND BRONCHIAL SUBMUCOSAL INTERLEUKIN-13 EXPRESSION IN ASTHMA AND EOSINOPHILIC BRONCHITIS
S9 IL-17 STIMULATES IL-8 RELEASE IN PRIMARY EPITHELIAL CELL CULTURES DERIVED FROM LUNG ALLOGRAFTS
S10 FIBROBLASTS AS A POTENT SOURCE OF CXCL8 IN TUBERCULOSIS
S11 IL-4δ2 AND TH2 CYTOKINES IN HUMAN PULMONARY TUBERCULOSIS
S12 RECENT TRENDS IN EPIDEMIOLOGY AND HEALTHCARE UTILISATION FOR ASTHMA
S13 ASTHMA PREVALENCE IN 1973, 1988, AND 2003
S14 INTERNATIONAL TRENDS IN ASTHMA ADMISSIONS
S15 MATERNAL SMOKING DURING PREGNANCY AND IN EARLY CHILDHOOD AS A RISK FACTOR FOR ASTHMA IN LATER LIFE
S16 AN ONGOING CONFIDENTIAL ENQUIRY INTO ASTHMA DEATHS IN PATIENTS AGED <65 YEARS
S17 MULTISLICE COMPUTED TOMOGRAPHY PROVIDES AN ACCURATE MEASURE OF RIGHT VENTRICULAR VOLUME IN PULMONARY HYPERTENSION
S18 CONSTRAST ENHANCED CARDIAC MAGNETIC RESONANCE IMAGING PROVIDES A NOVEL MARKER OF MYOCARDIAL INJURY IN PATIENTS WITH SEVERE PULMONARY HYPERTENSION
S19 INCREASED PULMONARY ARTERY TO AORTIC RATIO MEASURED USING MAGNETIC RESONANCE IMAGING IDENTIFIES PATIENTS WITH PULMONARY HYPERTENSION
S20 THE RELATION BETWEEN OUTCOME AND CTPA MEASUREMENTS IN ACUTE PULMONARY EMBOLISM
S21 PULMONARY ANGIOGRAPHY OR V/Q SCINTIGRAPHY IN PREGNANCY: IMPLICATIONS FOR CLINICAL GOVERNANCE FROM A SURVEY OF DOCTORS AND THEIR KNOWLEDGE OF RADIATION EXPOSURE
S22 ENDOSTATIN LEVELS IN WEGENER’S GRANULOMATOSIS: A RELATION WITH ALVEOLAR INFLAMMATION
S23 REDOX BASED MECHANOTRANSDUCTION IN ALVEOLAR EPITHELIAL CELLS
S24 NON-BRONCHOSCOPIC LAVAGE CANNOT DIFFERENTIATE BETWEEN PATIENTS WITH OR AT RISK FROM ACUTE RESPIRATORY DISTRESS SYNDROME
S25 BRONCHO-ALVEOLAR LAVAGE SEMIQUANTITATIVE VERSUS BLIND TRACHEAL ASPIRATE CULTURE IN DIAGNOSIS OF NOSOCOMIAL PULMONARY INFECTION IN VENTILATED “AT RISK” AND ARDS PATIENTS
S26 CLINICALLY SILENT GASTRIC ASPIRATION IS COMMON IN LUNG ALLOGRAFTS
S27 EFFICACY OF LOW AND HIGH DOSE INHALED CORTICOSTEROID IN SMOKERS VERSUS NON-SMOKERS WITH MILD ASTHMA
S28 PLASMA CONCENTRATIONS OF FLUTICASONE AND BUDESONIDE FOLLOWING INHALATION: THE EFFECT OF METHACHOLINE INDUCED AIRFLOW OBSTRUCTION
S29 RELATIVE AIRWAY AND SYSTEMIC EFFECTS OF HIGH DOSE CICLESONIDE AND FLUTICASONE PROPIONATE IN ASTHMA
S30 ORAL BUT NOT INCREASED DOSE INHALED CORTICOSTEROIDS REDUCE ALVEOLAR NITRIC OXIDE CONCENTRATION IN ADULTS WITH REFRACTORY ASTHMA
S31 THE EFFECT OF PROVIDING A SINGLE INHALER CONTAINING FORMOTEROL AND BUDESONIDE TO BE USED ONCE DAILY AND AS REQUIRED ON INHALED BUDESONIDE USE AND ASTHMA CONTROL IN POORLY COMPLIANT PATIENTS
S32 ANNUAL INCREASE IN BODY MASS INDEX IN CHILDREN WITH ASTHMA ON INHALED STEROIDS
S33 THE STUDY OF CYSTIC FIBROSIS AND ACUTE RENAL FAILURE (SCARF PROJECT): CASE SERIES
S34 URINARY AND FAECAL INCONTINENCE IN ADULTS WITH CYSTIC FIBROSIS
S35 INCREASED INCIDENCE OF PNEUMOTHORAX IN CYSTIC FIBROSIS PATIENTS COLONISED BY BURKHOLDERIA CENOCEPACIA
S36 INSPIRATORY MUSCLE TRAINING IN ADULT PATIENTS WITH CYSTIC FIBROSIS: A RANDOMISED CLINICAL TRIAL TO EVALUATE THE EFFICACY OF THE TEST OF INCREMENTAL RESPIRATORY ENDURANCE (TIRE)
S37 GROWING OLD WITH CYSTIC FIBROSIS
S38 HEALTH RELATED QUALITY OF LIFE AND FUTURE TREATMENT PREFERENCES OF PATIENTS WITH COPD ADMITTED TO UK CRITICAL CARE UNITS FROM CAOS: THE COPD & ASTHMA OUTCOME STUDY
S39 OUTCOME PREDICTION FOR ADMISSIONS WITH COPD TO UK CRITICAL CARE UNITS FROM CAOS: THE COPD & ASTHMA OUTCOME STUDY
S40 EFFECT OF BRONCHOSCOPIC LUNG VOLUME REDUCTION ON DYNAMIC HYPERINFLATION AND EXERCISE IN EMPHYSEMA
S41 OUTCOMES AFTER LUNG TRANSPLANTATION FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE: 16 YEARS’ EXPERIENCE AT A UK CENTRE
S42 PALLIATIVE CARE NEEDS OF COPD PATIENTS IN THE LAST YEAR OF LIFE
S43 COPD DEATH: FACING THE PROBLEM
S44 DOES POSITIVE AIRWAY PRESSURE THERAPY (PAP) PROVIDE A SYMPTOMATIC BENEFIT AT LOW LEVELS OF COMPLIANCE IN OBSTRUCTIVE SLEEP APNOEA PATIENTS?
S45 SLEEP DISORDERED BREATHING IN VERY SEVERE OBESE SUBJECTS (BMI>50 KG/M2): EFFECT OF ONE NIGHT OF CPAP
S46 WHAT EXPLAINS THE SEX DIFFERENCE IN MORTALITY IN TREATED OBSTRUCTIVE SLEEP APNOEA PATIENTS?
S47 SLEEP DISORDERED BREATHING IN VERY SEVERE OBESE SUBJECTS (BMI >50 KG/M2): SEX DIFFERENCES
S48 CPAP does not reduce 24 hour blood pressure in hypertensive obstructive sleep apnoea patients without daytime sleepiness
S49 ASTHMATIC BRONCHIAL EPITHELIAL CELLS HAVE A DEFICIENT INNATE IMMUNE RESPONSE TO INFECTION WITH RHINOVIRUS
S50 INFLAMMATORY MEDIATORS RELEASE FROM ASTHMATIC AND NON-ASTHMATIC BRONCHIAL EPITHELIAL CELLS FOLLOWING INFECTION WITH RHINOVIRUS
S51 DISCOVERY OF PROTEINS WITH ROLE IN DEFENCE AGAINST INFECTION
S52
S53 CHARACTERISATION OF NEUTROPHIL STIMULATING MEDIATORS IN CYSTIC FIBROSIS SPUTUM
S54 INAPPROPRIATE REFERRALS TO THE LUNG CANCER CLINIC
S55 ARE RAPID ACCESS LUNG CANCER CLINICS TOO QUICK? THE PATIENT’S VIEW
S56 SOCIAL DEPRIVATION AS A RISK FACTOR FOR INPATIENT PRESENTATION WITH LUNG CANCER
S57 BASELINE SURVEY OF PRACTICE IN DIAGNOSIS AND STAGING OF CARCINOMA OF THE BRONCHUS
S58 THE ACCEPTABILITY OF NURSE LED LUNG CANCER FOLLOW UP
S59 LUNG CANCER SURGERY: HOW WELL ARE WE DOING?
S60 THICKENING OF THE EPITHELIAL RETICULAR BASEMENT MEMBRANE IN PRESCHOOL CHILDREN WITH TROUBLESOME WHEEZE
S61 ARE CHILDHOOD ASTHMA PRESENTATIONS IN DECLINE? EVIDENCE FROM PRIMARY CARE
S62 THE RELATIVE BENEFITS AND ACCEPTABILITY OF METERED DOSE INHALERS AND NEBULISERS TO TREAT ACUTE ASTHMA IN PRESCHOOL CHILDREN
S63 THE RELATION BETWEEN EXHALED NITRIC OXIDE, PULMONARY FUNCTION, AND CHILDHOOD WHEEZE
S64 A CLUSTER RANDOMISED INTERVENTION TRIAL OF ASTHMA CLUBS TO IMPROVE QUALITY OF LIFE IN PRIMARY SCHOOL CHILDREN—THE SCHOOL CARE AND ASTHMA MANAGEMENT PROJECT (SCAMP)
S65 CAN MATERNAL ATOPIC HISTORY OR ATOPIC STATUS BE USED TO PREDICT ATOPY IN THEIR CHILDREN?
S66 PIVOT TRIAL: A MULTICENTRE RANDOMISED EQUIVALENCE TRIAL TO COMPARE ORAL AND IV TREATMENT FOR COMMUNITY ACQUIRED PNEUMONIA IN CHILDREN
S67 COMMUNITY ACQUIRED PNEUMONIA REQUIRING ADMISSION TO HOSPITAL IS ASSOCIATED WITH CHRONIC RESPIRATORY MORBIDITY IN CHILDHOOD
S68 SPUTUM CULTURE: IS IT WORTH THE EFFORT?
S69 USEFULNESS OF CURB, CURB-65, AND CRB-65 CRITERIA IN PREDICTING MORTALITY: A COMPILATION STUDY OF TWO PROSPECTIVE COHORTS OF COMMUNITY ACQUIRED PNEUMONIA
S70 AN AUDIT OF PNEUMONIA DEATHS IN A DISTRICT HOSPITAL
S71 TUMOUR ISLET MACROPHAGES MARKEDLY IMPROVE SURVIVAL IN NON SMALL CELL LUNG CANCER
S72 GENOME WIDE ANALYSIS OF LOH BY SNP MICROARRAYS TO DEMONSTRATE SEQUENTIAL CHROMOSOMAL LOSS IN INVASIVE LUNG CANCER COMPARED TO ITS EPITHELIAL ORIGIN
S73 N7-METHYLDEOXYGUANOSINE AND OXIDATIVE DNA ADDUCTS ASSOCIATIONS WITH LUNG CARCINOMA AND SMOKING
S74 PROGNOSTIC SIGNIFICANCE OF KI67 ACTIVITY IN NSCLC
S75 THE USE OF FUZZY LOGIC BASED TUMOUR MARKERS FOR DIAGNOSIS OF LUNG CANCER
S76 CYSTIC FIBROSIS MICE DISPLAY INCREASED ADHERENCE OF PSEUDOMONAS AERUGINOSA TO RESPIRATORY EPITHELIA OF A SIMILAR DEGREE TO THAT OBSERVED IN HUMANS
S77 RECOMBINANT SENDAI VIRUS VECTOR TO EVALUATE VECTOR DISTRIBUTION IN A LARGE ANIMAL MODEL OF LUNG GENE TRANSFER
S78 ANALYSIS OF THE EFFECT OF INFLAMMATORY GENE POLYMORPHISMS ON CLINICAL PHENOTYPE IN CYSTIC FIBROSIS
S79 TRANSFORMING GROWTH FACTOR β1 AND AIRWAY REMODELLING IN CHILDREN WITH CYSTIC FIBROSIS
S80 NEOPTERIN EXCRETION AND RNA TURNOVER IN ADULT PATIENTS WITH CYSTIC FIBROSIS
S81 LOCALISATION OF A FURTHER GENE FOR HEREDITARY HAEMORRHAGIC TELANGIECTASIA ASSOCIATED WITH PULMONARY ARTERIOVENOUS MALFORMATIONS
S82 MYELOID ZINC FINGER (MZF)-1: A NOVEL FAMILY OF ENDOTHELIAL CELL TRANSCRIPTION FACTORS IMPLICATED IN REGULATION OF ENDOGLIN GENE EXPRESSION AND ENDOTHELIAL CELL PROLIFERATION
S83 THE ROLE OF CYCLOOXYGENASE-2 AND ITS INTRACELLULAR SIGNALLING PATHWAYS IN THE HYPOXIC REGULATION OF GROWTH OF PERIPHERAL PULMONARY ARTERY SMOOTH MUSCLE CELLS
S84 LINKS BETWEEN LUNG DEVELOPMENT AND DISEASE
S85 AIRWAY SURFACE LIQUID HEIGHT AND NASAL POTENTIAL DIFFERENCE MEASUREMENTS IN FABP-CF KNOCKOUT MICE: A CORE FACILITY FOR SCREENING OF NON-VIRAL GENE TRANSFER AGENTS
S86 IDENTIFICATION OF A TRPM7-LIKE CATION CHANNEL IN HUMAN LUNG MAST CELLS
S87 CHARACTERISTICS OF OPTIMALLY PRESCRIBED INDIVIDUAL STRENGTH TRAINING WITHIN A STANDARD 7 WEEK PULMONARY REHABILITATION PROGRAMME
S88 PROLONGED PULMONARY REHABILITATION MAY LEAD TO GREATER IMPROVEMENT IN EXERCISE CAPACITY AND HEALTH RELATED QUALITY OF LIFE
S89 PULMONARY REHABILITATION: COPD SEVERITY AND FUNCTIONAL OUTCOME
S90 THE EFFECT OF AMBULATORY OXYGEN IN PATIENTS WHO DESATURATE ON EXERTION DURING A PULMONARY REHABILITATION PROGRAMME
S91 A PROTOCOL FOR AMBULATORY OXYGEN ASSESSMENT
S92 SHORT TERM EFFICACY OF AMBULATORY OXYGEN THERAPY: A COCHRANE SYSTEMATIC REVIEW
S93 A RANDOMISED TRIAL OF OUTPATIENT VERSUS INPATIENT INITIATION OF NON-INVASIVE VENTILATION IN NOCTURNAL HYPOVENTILATION DUE TO NEUROMUSCULAR AND CHEST WALL DISEASE
S94 RANDOMISED CONTROLLED TRIAL OF NON-INVASIVE VENTILATION IN MOTOR NEURONE DISEASE
S95 ASSESSMENT OF SLEEP IN NEUROMUSCULAR DISEASES
S96 NIV FACE MASK DESIGN: EFFECT ON TRIGGERING TIME AND INSPIRATORY DURATION
S97 A STUDY OF PATIENT ATTITUDES TOWARDS NON-INVASIVE VENTILATORY SUPPORT AND RELATION TO HEALTH STATUS IN COPD
S98 UK ASTHMA MANAGEMENT—CHARACTERISED BY SEX DIFFERENCES AND POOR CONTROL
S99 IMPLEMENTING ASTHMA ACTION PLANS: PRACTICE NURSE TRAINING IN PATIENT CENTRED COMMUNICATION SKILLS HAS NO IMPACT ON PATIENT OUTCOMES
S100 REDUCING ASTHMA EXACERBATIONS IN PRACTISE: AN OBSERVATIONAL STUDY
S101 AN APPROACH TO THE IDENTIFICATION AND MANAGEMENT OF POOR TREATMENT CONCORDANCE IN POTENTIALLY LIFE THREATENING ASTHMA
S102 WHERE NEXT IN CLINICAL ASTHMA RESEARCH? AN INNOVATIVE APPROACH TO RESEARCH PRIORITISATION
S103 TRANSBRONCHIAL NEEDLE ASPIRATION IN THE UK: A NATIONAL SURVEY
S104 ENDOBRONCHIAL AND ENDOSCOPIC ULTRASOUND GUIDED REAL-TIME FINE NEEDLE ASPIRATION FOR STAGING OF THE MEDIASTINUM IN LUNG CANCER
S105 VALUE OF BRONCHOSCOPY IN THE DIAGNOSIS OF LUNG CANCER IN PATIENTS WITH PLEURAL EFFUSIONS
S106 ENDOBRONCHIAL DIATHERMY TO TREAT LARGE AIRWAY OBSTRUCTION—YOU CAN DO IT TOO
S107 PALLIATION OF BENIGN/MALIGNANT AIRWAY OBSTRUCTION WITH ULTRAFLEX STENTS AND RIGID BRONCHOSCOPY
S108 A COMPARATIVE ANALYSIS OF SIXTEEN SLICE VIRTUAL COMPUTERISED TOMOGRAPHIC BRONCHOSCOPY AND CONVENTIONAL FIBRE OPTIC VIDEO BRONCHOSCOPY IN PATIENTS WITH SUSPECTED THORACIC MALIGNANCY
S109 BTS GUIDELINES FOR ASSESSMENT OF FITNESS FOR LUNG CANCER SURGERY—ARE THEY USEFUL?
S110 THE INFLUENCE OF AGE AND SEX IN PATIENTS REFERRED FOR LUNG CANCER SURGERY IN DETERMINING THE OUTCOME FROM SURGERY
S111 IS ATRIAL FIBRILLATION AFTER LUNG RESECTION DEPENDENT ON THE EXTENT OF RESECTION?
S112 DOES THE OPERATIVE INDICATION INFLUENCE THE OUTCOME OF SURGERY FOR EMPHYSEMA?
S113 BRONCHIAL CARCINOID TUMOURS: SURGICAL MANAGEMENT AND LONG TERM OUTCOME
S114 TRACHEAL RESECTION AND RECONSTRUCTION: 12 YEAR EXPERIENCE
S115 TUBERCULOSIS IN LONDON: PREVALENCE OF DISEASE AND RISK FACTORS FOR POOR ADHERENCE, DRUG RESISTANCE, AND RELAPSE
S116 TRENDS IN ANTI-TUBERCULOSIS DRUGS RESISTANCE IN ENGLAND AND WALES 1998–2001
S117 TREATMENT FAILURE IN LATENT TB INFECTION
S118 THE DEVELOPMENT OF TUBERCULOSIS IN PATIENTS RECEIVING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY FOR HIV INFECTION
S119 MEDIASTINAL LYMPHADENOPATHY: IS EUS-FNA USEFUL FOR THE DIFFERENTIATION BETWEEN TUBERCULOSIS AND SARCOIDOSIS?
S120 ROLE OF CLINICAL, PHYSIOLOGICAL, AND RADIOLOGICAL SCORES IN PREDICTING CHANGE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS AND SARCOIDOSIS
S121 SERUM KL-6 LEVELS ARE PREDICTIVE OF OUTCOME IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
S122 THE RELATION BETWEEN LUNG PHYSIOLOGY AND SECONDARY PULMONARY HYPERTENSION IN USUAL INTERSTITIAL PNEUMONIA
S123 MANAGEMENT OF DIFFUSE PARENCHYMAL LUNG DISEASE: A NATIONAL BENCHMARKING EXERCISE
S124 THE BRITISH ORPHAN LUNG DISEASE (BOLD) PROJECT: AN INITIAL DATABASE REPORT
S125 A STUDY TO COMPARE THE EFFICIENCY OF STERILE TALC, TETRACYCLINE, AND BLEOMYCIN AS SCLEROSING AGENTS FOR MEDICAL PLEURODESIS IN THE TREATMENT OF MALIGNANT PLEURAL EFFUSIONS
S126 THE ROLE OF THE BLIND PERCUTANEOUS PLEURAL BIOPSY IN THE INVESTIGATION OF EXUDATIVE PLEURAL EFFUSIONS
S127 PREDICTORS OF SURVIVAL IN PATIENTS WITH PLEURAL INFECTION BUT WITHOUT CANCER: RESULTS FROM THE MRC/BTS MIST TRIAL, ICTN 39138989
S128 COMPLICATIONS OF INTERCOSTAL CHEST DRAINS
S129 THE EFFECTS OF PLEURAL FLUID DRAINAGE ON OXYGENATION IN MECHANICALLY VENTILATED PATIENTS AFTER CARDIAC SURGERY
S130 SETTING UP A MEDICAL THORACOSCOPY SERVICE: SAFETY AND EFFICACY
S131 IDIOPATHIC PULMONARY FIBROSIS: A RELATION BETWEEN INFECTION AND INFLAMMATION?
S132 SIMVASTATIN INHIBITS GROWTH FACTOR EXPRESSION AND MODULATES PROFIBROTIC MARKERS IN HUMAN LUNG FIBROBLASTS
S133 NOVEL TRANSFORMING GROWTH FACTOR BETA TRANSCRIPTIONAL TARGETS IN ADULT LUNG FIBROBLASTS IDENTIFIED BY MICROARRAY ANALYSIS
S134 OLIGONUCLEOTIDE MICROARRAY ANALYSIS REVEALS COORDINATED EXPRESSION OF EXTRACELLULAR MATRIX ASSOCIATED GENES IN PULMONARY FIBROSIS IN VITRO
S135 A FUNCTIONAL POLYMORPHISM IN THE PROMOTER REGION OF THE CD86 (B7.2) GENE IS ASSOCIATED WITH SYSTEMIC SCLEROSIS
P0 OBJECTIVE ASSESSMENT OF COUGH IN ASTHMA: COUGH RATE IS A USEFUL AND REPEATABLE MEASURE
P1 OBJECTIVE MONITORING OF COUGH IN CHRONIC COUGH PATIENTS
P2 RELATIONSHIPS BETWEEN OBJECTIVE MEASURES OF COUGH AND SURROGATE MARKERS OF AIRWAY INFLAMMATION IN ASTHMA
P3 THE EFFECT OF PSYCHOLOGICAL INTERVENTIONS ON THE COUGH REFLEX
P4 ASSESSMENT OF ANTITUSSIVE EFFICACY OF DEXTROMETHORPHAN IN SMOKING RELATED COUGH: OBJECTIVE VERSUS SUBJECTIVE
P5 THE CLINICAL HISTORY IN REFLUX COUGH
P6 LAPAROSCOPIC NISSEN FUNDOPLICATION FOR REFLUX COUGH
P7 COULD CAPSAICIN ACT INTRACELLULARLY?
P8 EXPRESSION OF THE VANILLOID RECEPTOR (TRPV1) IN BRONCHI FROM PATIENTS WITH CHRONIC COUGH
P9 VARIABILITY OF EXHALED BREATH CONDENSATE PH IN HEALTHY SUBJECTS
P10 8-ISOPROSTANE AND LTB4 IN EXHALED BREATH CONDENSATE
P11 DEVELOPING METHODS FOR DETERMINING DILUTION FACTOR AND MEASURING LOW GLUCOSE CONCENTRATIONS IN EXHALED BREATH CONDENSATE
P12 ACID INJURY ALTERS THE VEGF/SVEGFR1 RATIO IN EPITHELIAL CELLS
P13 TOPICAL INSULIN INCREASES POTENTIAL DIFFERENCE ACROSS HUMAN NASAL EPITHELIUM
P14 SYMPTOM AND PEAK FLOW CHANGES DURING THE COMMON COLD AND AT EXACERBATION IN PATIENTS WITH COPD
P15 HOSPITAL ASSESSMENT IS NOT REQUIRED FOR HOME CARE OF COPD EXACERBATION
P16 DO “COMFORT VISITS” REDUCE HOSPITAL RE-ADMISSIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)? A PILOT STUDY
P17 REDUCTION OF HOSPITAL ADMISSIONS WITH AN INTEGRATED COPD PROGRAMME IN EAST LINCOLNSHIRE
P18 NUMBER OF ADMISSIONS PREVENTED BY INCREASING THE UPTAKE OF INFLUENZA VACCINATION IN THE TRAFFORD OVER 65 YEARS POPULATION
P19 EFFECTIVENESS OF AN OUTREACH COPD TEAM IN REDUCING HOSPITAL ADMISSIONS
P20 DRUG USE PROFILES AFTER HOSPITALISATION FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE NETHERLANDS AND THE RISK ON RE-HOSPITALISATION
P21 A STUDY OF PATIENT ATTITUDES TO INVASIVE VENTILATION IN COPD
P22 AUDIT OF NIV IN PATIENTS WITH SEVERE RESPIRATORY ACIDOSIS (PH<7.25)
P23 LONGITUDINAL MEASUREMENT OF EXHALED NITRIC OXIDE, EXHALED CARBON MONOXIDE, AND EXHALED BREATH CONDENSATE PH AND NITRITE LEVELS DURING AN ASTHMA EXACERBATION
P24 CLINICAL EVALUATION OF A NEW ELECTRONIC AND A STANDARD PORTABLE PEAK FLOW METER
P25 ASSOCIATION BETWEEN ALVEOLAR NITRIC OXIDE CONCENTRATION AND BRONCHOALVEOLAR LAVAGE BUT NOT BRONCHIAL WASH EOSINOPHIL COUNT IN PATIENTS WITH MILD ASTHMA
P26 EVH: A USEFUL CHALLENGE FOR DIAGNOSING EIA IN OLYMPIC ATHLETES
P27 THE CHARACTERISTIC PATTERNS OF BREATHING IN ASTHMA AS MEASURED BY RESPIRATORY INDUCTANCE PLETHYSMOGRAPHY (RIP)
P28 3HE LUNG SCANNING IDENTIFIES DIFFERENT PHENOTYPES OF SEVERE ASTHMA
P29 COMPARISON OF ABBREVIATED OR FULL DOSE RESPONSE CHALLENGE PROTOCOLS WITH ADENOSINE MONOPHOSPHATE IN ASSESSING AIRWAYS HYPER-RESPONSIVENESS
P30 INCIDENCE OF DYSFUNCTIONAL BREATHING IN CONSECUTIVE, UNSELECTED PATIENTS PRESENTING TO A GENERAL RESPIRATORY OUTPATIENT DEPARTMENT OVER A 7 YEAR PERIOD
P31 SHOULD ASTHMATIC CHILDREN HAVE OPEN FOOD CHALLENGES?
P32 CONCURRENT CHEMORADIATION USING CISPLATINUM, VINORELBINE, AND RADICAL RADIOTHERAPY WITH 20 FRACTIONS IN 4 WEEKS FOR PATIENTS WITH INOPERABLE NSCLC AND GOOD PERFORMANCE STATUS
P33 PULMONARY FUNCTION AFTER RADICAL CONCURRENT CHEMORADIOTHERAPY FOR INOPERABLE NSCLC
P34 SINGLE FRACTION RADIOTHERAPY TO DRAIN OR THOROSCOPY SITE AS EFFECTIVE PROPHYLAXIS FOR TUMOUR SEEDING IN MESOTHELIOMA
P35 ACCELERATED RADICAL RADIOTHERAPY: AN ALTERNATIVE TO CHART
P36 PHOTODYNAMIC THERAPY (PDT) IN LUNG CANCER WITH DISEASE LIMITED TO ENDOBRONCHIAL LESIONS
P37 CARCINOMA IN SITU OF THE LUNG: AN AUDIT OF INCIDENCE, TREATMENT AND OUTCOME
P38 THE NUTRITIONAL STATUS OF PATIENTS WITH OPERABLE LUNG CANCER AND ITS IMPACT ON OUTCOME FROM LUNG CANCER SURGERY: PROSPECTIVE STUDY AT A UK CARDIOTHORACIC CENTER
P39 PULMONARY FUNCTION AND EXERCISE TESTING AS PREDICTORS OF POST-OPERATIVE COMPLICATIONS AND PROLONGED HOSPITALISATION AFTER LUNG RESECTION
P40 THE IMPACT OF LUNG CANCER SURGERY ON QUALITY OF LIFE, LUNG FUNCTION, AND EXERCISE CAPACITY
P41 WHAT FACTORS PREDICT LOCAL TUMOUR RECURRENCE FOLLOWING BIOPSY IN MALIGNANT MESOTHELIOMA?
P42 INTERFACE OF LUNG CANCER AND PALLIATIVE CARE SERVICES: A CANCER NETWORK PERSPECTIVE
P43 OCCUPATIONAL ASTHMA: A NATIONAL AUDIT OF DIAGNOSTIC PRACTICE
P44 OCCUPATION AND RESPIRATORY SYMPTOMS IN A POPULATION SURVEY OF 45−69 YEAR OLDS IN NORTHEAST ENGLAND
P45 DIFFERENCES IN RESPIRATORY SYMPTOMS BETWEEN IRRITANT AND ALLERGEN EXPOSED WORKERS
P46 OUTBREAK OF EXTRINSIC ALLERGIC ALVEOLITIS AT A CAR ENGINE PLANT
P47 OCCUPATIONAL LUNG DISEASE, DIAGNOSIS, AND COMMUNICATION: FACT OR FICTION?
P48 WORK RELATED RESPIRATORY AND NASAL SYMPTOMS IN UK BAKERS: RELATIONSHIP TO WHEAT FLOUR AND ENZYME SENSITISATION
P49 HYDROXYL RADICAL PRODUCTION MEDIATED BY PRO-OXIDATIVE INTERACTIONS OF VANADIUM WITH HUMAN NEUTROPHILS
P50 LATENT VIRAL INFECTION: A POSSIBLE ROLE IN THE PATHOGENESIS OF COPD
P51 ADENOVIRUS E1A IS INFREQUENTLY DETECTED IN RESPIRATORY SECRETIONS FROM COPD PATIENTS USING REAL TIME PCR
P52 CHRONIC SPUTUM PRODUCTION IS ASSOCIATED WITH INCREASED LOWER AIRWAY BACTERIAL COLONISATION IN COPD
P53 PERIPHERAL BLOOD NEUTROPHILS IN STABLE COPD AND AT EXACERBATION
P54 PERIPHERAL BLOOD T CELL SUBSETS IN STABLE COPD AND AT EXACERBATION
P55 GMCSF IS ELEVATED IN COPD PATIENTS IN COMPARISON TO NON-OBSTRUCTED SMOKERS
P56 RELATIONSHIP BETWEEN DISEASE SEVERITY AND AIRWAY INFLAMMATORY RESPONSE AT EXACERBATIONS OF COPD
P57 OUTPATIENT PULMONARY REHABILITATION FOR NON-COPD PATIENTS
P58 USE OF THE HOSPITAL ANXIETY AND DEPRESSION SCALE IN PULMONARY REHABILITATION
P59 DOES A MODIFIED BODE INDEX PREDICT OUTCOME OF PULMONARY REHABILITATION?
P60 PULMONARY REHABILITATION: COPD SEVERITY AND IMPROVEMENT IN WALKING DISTANCE
P61 PULMONARY REHABILITATION (PR): QUALITY OF LIFE (QOL) OUTCOME BY CLASSIFICATION OF COPD SEVERITY
P62 EARLY OUTPATIENT PULMONARY REHABILITATION FOLLOWING HOSPITALISATION FOR ACUTE EXACERBATIONS OF COPD: EFFECTS ON HOSPITAL RESOURCE USAGE
P63 HOW MANY PATIENTS PRESCRIBED SHORT BURST OXYGEN MEET THE RCP CRITERIA FOR AMBULATORY OXYGEN?
P64 EXERCISE DURING HYPOXIC CONDITIONS IN COPD AND PULMONARY HYPERTENSION (PH)
P65 THE INFLUENCE OF PAO2 LEVELS AND SOCIAL CIRCUMSTANCES ON HOSPITAL OR HOME CARE IN PATIENTS WITH ACUTE COPD EXACERBATIONS
P66 IS AIR TRAVEL UNDERTAKEN BY THOSE WITH LUNG DISEASE AND IS IT SAFE?
P67 OXYGEN CONCENTRATORS: ARE THEY CORRECTLY PRESCRIBED AND WHEN ARE THEY COST EFFECTIVE?
P68 OXYGEN THERAPY PRESCRIPTION STICKERS: DO THEY IMPROVE COMPLIANCE?
P69 EFFECT OF OXYGEN THERAPY ON CARBON DIOXIDE RETENTION IN PATIENTS REQUIRING LONG TERM OXYGEN
P70 THE EFFECT OF UNCONTROLLED OXYGEN THERAPY ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS AT RISK OF CO2 RETENTION
P71 ARE PATIENTS ADEQUATELY ASSESSED PRIOR TO PERCUTANEOUS LUNG BIOPSY?
P72 COMPLICATIONS DURING BRONCHOSCOPY: DOES IT MATTER WHICH SEDATING AGENT IS USED?
P73 BRONCHIAL STENT INSERTION USING FIBREOPTIC BRONCHOSCOPY, IMAGE GUIDANCE AND CONSCIOUS SEDATION
P74 DOES SEDATION DELAY THE RETURN OF SAFE SWALLOWING FOLLOWING FIBREOPTIC BRONCHOSCOPY?
P75 UNSEDATED BRONCHOSCOPY—ACCEPTABILITY TO PATIENTS AND OPERATORS
P76 SURVEY OF THE PRACTICE OF INTERVENTIONAL BRONCHOSCOPY IN UK
P77 CUSUM ANALYSIS TO ASSESS COMPETENCE AT TRANSBRONCHIAL NEEDLE ASPIRATION (TBNA): HOW MANY ARE ENOUGH?
P78 A COMPARISON OF TWO CYTOLOGICAL METHODS FOR ANALYSIS OF BRONCHIAL BRUSH SPECIMENS IN LUNG CANCER
P79 AUTOMATED QUANTITATIVE SPUTUM CYTOLOGY IN THE DIAGNOSIS OF LUNG CANCER
P80 IMPACT OF THINPREP® 2000 ON THE DIAGNOSTIC UTILITY OF BRONCHOSCOPIC CYTOLOGY FROM PATIENTS SUSPECTED OF PRIMARY LUNG CARCINOMA
P81 GENOTYPIC RISK FACTORS FOR THE DEVELOPMENT OF THE BRONCHIOLITIS OBLITERANS SYNDROME (BOS) AFTER LUNG TRANSPLANTATION
P82 MATERNAL CLARA CELL SECRETORY PROTEIN (CC16) GENOTYPE IS ASSOCIATED WITH FEV1 IN ASTHMATIC CHILDREN
P83 FAMILIAL ASSOCIATION OF CHILDHOOD WHEEZY BRONCHITIS AND ASTHMA ONLY THROUGH THE MEN LINEAGE
P84 FAMILIAL SEGREGATION OF LUNG FUNCTION IN ASTHMATIC FAMILIES: BOTH PARENTS ARE IMPORTANT BUT MOTHER’S INFLUENCE MAY PREDOMINATE EARLIER
P85 GLUTATHIONE S-TRANSFERASES, OXIDATIVE STRESS AND SEASONAL ALLERGIC RESPONSES
P86 UNIFIED AIRWAY GENETICS
P87 THE ROLE OF A MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) FUNCTIONAL POLYMORPHISM IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
P88 CCR5 AND SARCOIDOSIS: ASSOCIATION WITH RADIOLOGICAL STAGES OF DISEASE
P89 THE C(–159)→T GENE POLYMORPHISM IN THE PROMOTER OF THE CD14 MONOCYTE RECEPTOR GENE IS ASSOCIATED WITH SARCOIDOSIS IN TWO WHITE POPULATIONS
P90 EVALUATING SPIRITUAL HEALING: A PRAGMATIC, SINGLE BLIND, THREE ARM RCT PILOT STUDY OF COMPLEMENTARY MEDICINE IN PATIENTS WITH ASTHMA
P91 EFFECT OF ADD ON THERAPY COMPARED WITH DOUBLING STEROID INHALATION IN BRONCHIAL ASTHMA
P92 CORTICOSTEROID THERAPY IN THE UNIFIED AIRWAY
P93 CICLESONIDE 80 µG OR 320 µG ONCE DAILY ACHIEVES LUNG FUNCTION IMPROVEMENT COMPARABLE WITH BUDESONIDE 200 µG TWICE DAILY IN PATIENTS WITH PERSISTENT ASTHMA
P94 THE INCIDENCE OF ADVERSE EVENTS IS COMPARABLE IN ASTHMA PATIENTS RECEIVING CICLESONIDE OR PLACEBO: RESULTS FROM A POOLED ANALYSIS
P95 ONCE DAILY CICLESONIDE IS EFFECTIVE IN THE TREATMENT OF ASTHMA
P96 ONCE DAILY CICLESONIDE IS AS EFFECTIVE AS TWICE DAILY FLUTICASONE PROPIONATE IN IMPROVING LUNG FUNCTION IN PATIENTS WITH ASTHMA
P97 IMPROVED ADHERENCE WITH ONCE DAILY VERSUS TWICE DAILY DOSING OF MOMETASONE FUROATE DRY POWDER INHALER (ASMANEX TWISTHALER)
P98 IMPROVED ASTHMA OUTCOMES ASSOCIATED WITH INHALED CORTICOSTEROID DELIVERY VIA A DRY POWDER RATHER THAN A METERED DOSE INHALER
P99 TRANSITION FROM CFC-BDP TO NON-CFC STEROID INCREASES SCHEDULED BUT NOT UNSCHEDULED HEALTHCARE
P100 STEPPING DOWN INHALED STEROIDS IN SEVERE ASTHMA WITH LONG ACTING BRONCHODILATORS: UTILISING EFFORT DEPENDENT AND INDEPENDENT MEASURES OF PULMONARY FUNCTION
P101 CORRELATION OF RCP-3 QUESTIONS WITH SAQLQ DEMONSTRATED BY THE TREATMENT OF SYMPTOMATIC PATIENTS WITH BUDESONIDE/FORMOTEROL (“SYMBICORT”)
P102 DOMICILIARY NEBULISER SERVICE: ARE NATIONAL GUIDELINES BEING LOCALLY IMPLEMENTED?
P103 DO PATIENTS ADMITTED TO INTENSIVE CARE WITH ASTHMA STILL DIE?
P104 HOME SLEEP STUDIES FOR EVALUATION OF SUSPECTED OBSTRUCTIVE SLEEP APNOEA SYNDROME (OSAS) IN CHILDREN
P105 WHICH OBESE CHILDREN SHOULD BE INVESTIGATED FOR OBSTRUCTIVE SLEEP APNOEA?
P106 ARE THE RECENT CHANGES IN THE DVLA D4 MEDICAL FORM SUFFICIENT TO INCREASE DETECTION OF OBSTRUCTIVE SLEEP APNOEA IN A HIGH RISK DRIVING POPULATION?
P107 IS THE EPWORTH SLEEPINESS SCALE (ESS) TOO SIMPLE A TOOL IN THE MEASUREMENT OF EXCESSIVE SLEEPINESS FOR OBSTRUCTIVE SLEEP APNOEA (OSA)?
P108 A PILOT STUDY TO ASSESS METHODS OF DETERMINING THE BURDEN OF OBSTRUCTIVE SLEEP APNOEA SYNDROME (OSAS) IN A MULTICULTURAL INNER CITY GENERAL PRACTICE
P109 IS A CPAP MASTERCLASS APPROACH TO STARTING CPAP THERAPY IN OBSTRUCTIVE SLEEP APNOEA (OSA) AS GOOD AS A 1/1 APPROACH?
P110 HIGH SUSPICION OF SLEEP APNOEA SYNDROME IN ATTENDERS AT A HYPERLIPIDAEMIA CLINIC
P111 PREVALENCE OF METABOLIC SYNDROME IN NEW ATTENDERS AT A SLEEP DISORDER BREATHING CLINIC
P112 MEASUREMENT OF AORTIC DISTENSIBILITY IN OBSTRUCTIVE SLEEP APNOEA HYPOPNOEA SYNDROME
P113 THE EFFECT OF POSTURE AND SLEEP STAGE ON SNORING SOUND LEVEL
P114 RELATIONSHIP BETWEEN REM EVENT RATES, REM CEREBRAL OXYGENATION, AND CPAP COMPLIANCE IN CONSECUTIVE SUBJECTS WITH OBSTRUCTIVE SLEEP APNOEA
P115 THE RELATIONSHIP BETWEEN MOUTH LEAK DURING A DAYTIME TRIAL OF CPAP AND MASK TYPE USED DURING SLEEP
P116 IS CANDIDIASIS A PROBLEM IN ADULTS WITH CYSTIC FIBROSIS? A PROSPECTIVE STUDY
P117 THE ROLE OF RESPIRATORY VIRAL AGENTS IN CYSTIC FIBROSIS
P118 REVIEW OF PSEUDOMONAS AERUGINOSA INFECTION WITHIN A SINGLE CF CENTRE
P119 ANTIBIOGRAM PATTERNS OF THE LIVERPOOL EPIDEMIC STRAIN (LES) OF PSEUDOMONAS AERUGINOSA
P120 TOBRAMYCIN NEBULISER SOLUTION (TOBI): A RENAL SPARING ALTERNATIVE TO INTRAVENOUS (IV) TOBRAMYCIN IN ACUTE PULMONARY EXACERBATIONS IN CF
P121 RENOPROTECTIVE EFFECT OF FOSFOMYCIN IN THE TREATMENT OF MULTIRESISTANT PSEUDOMONAS AERUGINOSA IN CF
P122 RENAL INTERACTION BETWEEN COLOMYCIN AND TOBRAMYCIN IN CF
P123 MEASURING ALVEOLAR AND BRONCHIAL NITRIC OXIDE IN CHILDREN WITH CYSTIC FIBROSIS AS A MARKER OF AIRWAY INFLAMMATION
P124 THE USE OF MOBILE PHONE TECHNOLOGY FOR EARLY DETECTION OF PULMONARY EXACERBATION OF CYSTIC FIBROSIS (CF): A TIME TO BE PRECISE
P125 A RE-AUDIT OF THE USE OF INTRAVENOUS PAMIDRONATE IN AN ADULT CYSTIC FIBROSIS CENTRE
P126 WHAT TRIGGERS REFERRALS FROM PRIMARY TO SECONDARY CARE IN POSSIBLE LUNG CANCER?
P127 APPROPRIATENESS OF REFERRAL TO A FAST TRACK CLINIC FOR PATIENTS SUSPECTED OF HAVING LUNG CANCER
P128 THE LUNG CANCER TWO WEEK WAIT: A PROSPECTIVE AUDIT
P129 COMPARISON OF A “ONE-STOP” LUNG CANCER CLINIC AND A MORE TRADITIONAL LUNG CANCER CLINIC IN A DISTRICT GENERAL HOSPITAL OVER A 1 YEAR PERIOD
P130 AUDIT OF A NEWLY SET UP “ONE-STOP” RAPID ACCESS LUNG CANCER CLINIC IN A DISTRICT GENERAL HOSPITAL
P131 UNPLANNED ADMISSIONS FOLLOWING THE DIAGNOSIS OF LUNG CANCER
P132 THE 31 DAY RULE IN THE MANAGEMENT OF LUNG CANCER: IS IT ACHIEVABLE?
P133 IS THERE LIGHT AT THE END OF THE TUNNEL? SYMPTOMS AND CHEST x ray help identify patients at high risk of lung cancer
P134 A CASE FOR BEDSIDE CHEST ULTRASOUND EXAMINATION BY CHEST PHYSICIANS
P135 MEDICAL THORACOSCOPY: A 5 YEAR FOLLOW UP SURVEY OF UK RESPIRATORY PHYSICIANS
P136 RESECTION RATES FOR PATIENTS WITH LUNG CANCER AT AN INNER CITY HOSPITAL, LONDON, UK 1999–2004
P137 THE CAMPHOR IN CLINICAL PRACTICE
P138 LUNG FUNCTION IN PULMONARY ARTERIAL AND CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION AND RESPONSE TO TREATMENT
P139 INCREMENTAL SHUTTLE WALKING TEST DISTANCE PREDICTS PROGNOSIS IN PATIENTS WITH PULMONARY HYPERTENSION TREATED WITH TARGETED PULMONARY VASCULAR THERAPY
P140 THE UTILITY OF PLASMA PRO-BNP IN ASSESSING DISEASE SEVERITY IN PULMONARY ARTERIAL HYPERTENSION
P141 AN AUDIT OF THE USE OF COMPUTED TOMOGRAPHY PULMONARY ANGIOGRAM (CTPA) FOR INVESTIGATION OF SUSPECTED PULMONARY EMBOLISM (PE) IN A DISTRICT GENERAL HOSPITAL
P142 USE OF NEBULISED ILOPROST THERAPY IN EARLY PREGNANCY IN PATIENTS WITH PULMONARY HYPERTENSION
P143 SURVIVAL IN PULMONARY HYPERTENSION - THE PAPWORTH EXPERIENCE
P144 COMPLICATIONS ASSOCIATED WITH PULMONARY THROMBOEMBOLISM (PTE) AND RISKS TO AMBULATORY CARE STRATEGIES
P145 MATERNAL RISKS OF PREGNANCY IN PATIENTS WITH PULMONARY ARTERIOVENOUS MALFORMATIONS
P146 PARADOXICAL EMBOLIC STROKE DUE TO PULMONARY ARTERIOVENOUS MALFORMATIONS OF ALL DEGREES OF SEVERITY
P147 DO MEDICAL OUTPATIENTS WANT “OUT OF HOURS” CLINICS?
P148 RESPIRATORY CARE UNITS: IS THERE A NEED IN A DISTRICT GENERAL HOSPITAL?
P149 SHOULD NON-PULMONARY SPECIALITIES HAVE ACCESS TO LUNG FUNCTION TESTS?
P150 AN EVALUATION OF A SPECIALISED PHYSIOTHERAPY/NURSE LED CLINIC FOR PATIENTS WITH BRONCHIECTASIS,
P151 RESPIRATORY HIGH DEPENDENCY UNIT; PROSPECTIVE ANALYSIS OF ITS BED SAVING IMPACT ON INTENSIVE CARE UNIT AND IN HOSPITAL MORTALITY
P152 ADHESION OF HUMAN LUNG MAST CELLS TO AIRWAY SMOOTH MUSCLE
P153 ACTIVATION OF HUMAN LUNG MAST CELLS BY MONOMERIC IGE
P154 QUANTITIVE DETERMINATION OF BASOPHIL ACTIVATION IN RESPONSE TO ASPERGILLUS IN ASTHMATIC AND NORMAL SUBJECTS
P155 CHEMOKINE CONCENTRATIONS IN INDUCED SPUTUM AND BRONCHOALVEOLAR LAVAGE IN EOSINOPHILIC BRONCHITIS, ASTHMA, AND NORMAL CONTROLS
P156 RELATIONSHIPS OF TOTAL IMMUNOGLOBULIN E, ALLERGIC SENSITISATION AND ASTHMA SEVERITY IN CHILDREN WITH ASTHMA
P157 OXIDATIVE STRESS DURING A RANDOMISED CONTROLLED TRIAL OF VITAMIN E SUPPLEMENTATION IN ATOPIC ASTHMA
P158 THE INCREASING WORKLOAD OF THE TUBERCULOSIS SERVICE IN A WESTERN EUROPEAN CITY
P159 PRELIMINARY FINDINGS FROM THE LONDON TB LINK PROJECT TARGETING HOMELESS AND MARGINALISED GROUPS
P160 A CASE CONTROL STUDY OF FOREIGN TRAVEL AS A RISK FACTOR FOR TUBERCULOSIS
P161 TARGETED MOBILE DIGITAL CHEST RADIOGRAPHY IN THE CONTROL OF TUBERCULOSIS IN HIGH RISK GROUPS IN LONDON: A PILOT PROJECT
P162 A COMPARISON OF TWO MODELS OF TUBERCULOSIS (TB) CLINIC SERVICES EXAMINING THE UTILITY OF TB SPECIALIST NURSE LED CLINICS
P163 MANAGEMENT OF TUBERCULOSIS IN HEALTHCARE WORKERS: ASSESSING KNOWLEDGE AMONG OCCUPATIONAL HEALTH NURSES
P164 SPINAL TUBERCULOSIS IN SE LONDON: DELAYS IN DIAGNOSIS AND RESPONSE TO TREATMENT
P165 THE RELATIONSHIP BETWEEN CT DEFINED PULMONARY TUBERULOSIS CAVITIES AND MYCOBACTERIAL LOAD AND CULTURE
P166 VALIDATION OF BLEACH DIGESTION OF SPUTUM IN THE DIAGNOSIS OF PULMONARY TUBERCULOSIS
P167 USE OF QUANTIFERON TB GOLD TEST IN INVESTIGATION OF UNEXPLAINED HIGH FREQUENCY OF POSITIVE HEAF TEST IN SCHOOL SCREENING
P168 SIMILAR HIGH FREQUENCY OF DETECTION OF PPD SPECIFIC CD4+ LYMPHOCYTES IN BRONCHOALVEOLAR LAVAGE IN HIV POSITIVE AND NEGATIVE TB PATIENTS
P169 AETIOLOGY OF BRONCHIECTASIS IN SECONDARY CARE
P170 IS THERE AN ASSOCIATION BETWEEN PARADOXICAL REACTIONS AND MYCOBACTERIUM TUBERCULOSIS STRAIN TYPE?
P171 DRUG RESISTANCE IS NOT ASSOCIATED WITH TREATMENT INTERRUPTION IN PATIENTS WITH TUBERCULOSIS
P172 REPEATABILITY OF MEASUREMENTS OF PEAK INSPIRATORY FLOW, MAXIMUM INSPIRATORY VOLUME, AND INSPIRED VITAL CAPACITY
P173 TPTEF/TE MEASURED SIMULTANEOUSLY BY NASAL CANNULAE AND PNEUMOTACHOGRAPH DURING MOUTH AND NOSE BREATHING
P174 RESPIRATORY AND PERIPHERAL MUSCLE STRENGTH IN COPD PATIENTS: STRATIFIED ACCORDING TO MRC GRADE
P175 EQ-5D QUALITY ADJUSTED LIFE YEARS (QALYS) DO NOT UNDERESTIMATE HEALTH OUTCOMES FOR PATIENTS WITH SEVERE COPD
P176 INFLUENCE OF INSPIRATORY LEVEL ON CT DENSITOMETRIC PARAMETERS
P177 MEASUREMENT OF DISEASE PROGRESSION IN ALPHA 1-ANTITRYPSIN DEFICIENCY USING CT DENSITOMETRY
P178 EXAMINATION OF THE RESPIRATORY SYSTEM: THE SENSITIVITY AND SPECIFICITY OF CLINICAL SIGNS ASSOCIATED WITH AIRWAY OBSTRUCTION
P179 THE PREVALENCE OF VOICE HANDICAP IN COPD
P180 INCREASING SEVERITY OF COPD IS ASSOCIATED WITH INCREASING NASAL AIRFLOW OBSTRUCTION
P181 LONG TERM CARDIOPULMONARY OUTCOME OF PRETERM, SMALL FOR GESTATIONAL AGE SUBJECTS
P182 EXPLORING THE PALLIATIVE CARE NEEDS OF PATIENTS WITH A NON-CANCER DIAGNOSIS
P183 WHICH OF EIGHT INHALER DEVICES IS BEST FOR ELDERLY PEOPLE? RANDOMISED OBSERVATIONAL STUDIES
P184 UNEXPLAINED DISCREPANCIES IN INHALER PRESCRIPTIONS WHEN ADMITTED TO HOSPITAL
P185 PRE DISCHARGE SPIROMETRY IN PATIENTS WITH COPD IS NOT ROUTINE PRACTICE IN HOSPITALS IN THE THAMES REGIONS
P186 TESTING WHAT WE TEACH IN COPD DESIGN AND TESTING OF A PATIENT QUESTIONNAIRE
P187 COPD IN NON-SMOKERS IN PRIMARY CARE
P188 PARTICIPATION IN TREATMENT DECISIONS IN PATIENTS WITH COPD AND RECURRENT BRONCHITIS: A QUALITATIVE STUDY
P189 SPRUCE: TIOTROPIUM IN A UK PRIMARY CARE MANAGED COPD POPULATION
P190 NUMBER NEEDED TO TREAT (NNT) ANALYSIS OF BUDESONIDE/FORMOTEROL VERSUS FORMOTEROL TO AVOID ONE CHRONIC OBSTRUCTIVE PULMONARY DIESEASE (COPD) EXACERBATION AND ITS IMPLICATIONS FOR HEALTH RELATED QUALITY OF LIFE
P191 POTENTIAL COST SAVINGS IN PRIMARY CARE BY IMPLEMENTING THE BTS GUIDELINES
P192 OVER AND UNDER TREATMENT OF SUBJECTS WITH AIRWAY DISEASE HIGHLIGHTED BY COMMUNITY SPIROMETRY TESTING
P193 A REVIEW OF SMOKING CESSATION SERVICES WITHIN A HOSPITAL SETTING
P194 A RCT EVALUATING THE BTS SMOKING CESSATION GUIDELINES WITH PATIENTS ATTENDING SECONDARY CARE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
P195 THE EFFECTIVENESS OF SMOKING POLICY IN NHS HOSPITALS
P196 IN HOSPITAL SMOKING CESSATION ADVICE: ARE WE DOING ENOUGH?